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Abstract
Purpose This short review aims to cover the more recent
and promising developments of carbon-11 (11C) labeling
radiochemistry and its utility in the production of novel
radiopharmaceuticals, with special emphasis on methods
that have the greatest potential to be translated for clinical
positron emission tomography (PET) imaging.
Methods A survey of the literature was undertaken to
identify articles focusing on methodological development
in 11C chemistry and their use within novel radiopharma-
ceutical preparation. However, since 11C-labeling chem-
istry is such a narrow field of research, no systematic
literature search was therefore feasible. The survey was
further restricted to a specific timeframe (2000–2016) and
articles in English.
Results From the literature, it is clear that the majority of
11C-labeled radiopharmaceuticals prepared for clinical PET
studies have been radiolabeled using the standard het-
eroatom methylation reaction. However, a number of
methodologies have been developed in recent years, both
from a technical and chemical point of view. Amongst
these, two protocols may have the greatest potential to be
widely adapted for the preparation of 11C-radiopharma-
ceuticals in a clinical setting. First, a novel method for the
direct formation of 11C-labeled carbonyl groups, where
organic bases are utilized as [11C]carbon dioxide-fixation
agents. The second method of clinical importance is a low-
pressure 11C-carbonylation technique that utilizes solvable
xenon gas to effectively transfer and react [11C]carbon
monoxide in a sealed reaction vessel. Both methods appear
to be general and provide simple paths to 11C-labeled
products.
Conclusion Radiochemistry is the foundation of PET
imaging which relies on the administration of a radio-
pharmaceutical. The demand for new radiopharmaceuticals
for clinical PET imaging is increasing, and 11C-radio-
pharmaceuticals are especially important within clinical
research and drug development. This review gives a
comprehensive overview of the most noteworthy 11C-la-
beling methods with clinical relevance to the field of PET
radiochemistry.
Keywords PET  Radiochemistry  Isotopic labeling 
Carbon-11  Radiopharmaceuticals
Introduction
Positron emission tomography (PET) is a highly sensitive
imaging modality that can provide in vivo quantitative
information of biological processes at a biochemical level
[1]. PET relies upon the administration of a chemical
probe, often called a radiopharmaceutical, that is labeled
with a short-lived positron-emitting radionuclide [e.g. 11C
(t1/2 = 20.4 min) and
18F (t1/2 = 109.7 min)]. Several PET
radiopharmaceuticals have been developed for imaging
applications, predominantly within oncology [2] and neu-
roscience [3, 4]. The development of novel radiopharma-
ceuticals requires multiple considerations, where aspects
like radionuclide selection, labeling position, metabolic
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stability, precursor synthesis, radiolabeling procedure,
automation, quality control and regulatory affairs all have
to be considered [5, 6].
Carbon-11 is one of the most useful radionuclides for
PET chemistry, since its introduction into a biologically
active molecule has minimal effects on the (bio)chemical
properties of the compound [7, 8]. In addition, there is a
vast literature on carbon-based chemistry that can be con-
sulted in the development of radiosynthetic procedures
with carbon-11. Moreover, the short half-life of 11C allows
for longitudinal in vivo studies with repeated injections in
the same subject (patient or animal) and on the same
experimental day. Although the advances in 11C chemistry
have enabled the preparation of a great number of radio-
labeled molecules, there are still relatively few that have
been applied for the direct preparation of novel radio-
pharmaceuticals for PET. The present review will provide
an overview of the most recent and promising develop-
ments within carbon-11 chemistry since year 2000.
General considerations in radiopharmaceutical
chemistry
A few general comments are required to provide a context
for a discussion of PET radiopharmaceutical production
[2, 5]. First of all, the radionuclides used in PET emit high-
energy radiation and, therefore, the traditional hands-on
manipulations used in synthetic chemistry are not feasible.
Thus, in order to avoid unnecessary radiation exposure,
radiolabeling is performed in fully automated and pre-
programmed synthesis modules housed inside lead-shiel-
ded fume hoods (hot-cells). One could say that radio-
chemistry, in particular that with 11C, is a hybrid science
between organic chemistry and engineering. Time is
another factor of major importance in PET chemistry. A
radiopharmaceutical used in PET is typically synthesized,
purified, formulated and analyzed within a timeframe of
roughly 2–3 physical half-lives of the employed radionu-
clide. For example, to obtain 11C-labeled radiopharma-
ceutical in optimal radiochemical yield (RCY), a
compromise has to be made between the chemical yield
and the radioactive decay. The chemical yield of a reaction
is thus not as important as the obtained radioactivity of the
target compound at end of synthesis. Furthermore, since
only trace amount of the radiolabeling synthon is used in
PET, the amount of the non-radioactive reagents is in large
excess, which implies that the reaction follows pseudo first-
order kinetics. By consequence, small impurities in
reagents or solvents may have a significant influence on the
reaction outcome. The radiochemist has to further consider
the specific activity (SA), which is a measure of the
radioactivity per unit mass of the final radiolabeled
compound. Since high SA is often required in neurore-
ceptor imaging studies to avoid saturation of the receptor
system, the methods that are highlighted in this review are
all non-carrier-added nature.
Carbon-11 chemistry
Carbon-11 is commonly generated via the 14N(p, a)11C
nuclear reaction. The reaction is performed by high-energy
proton bombardment of a cyclotron target containing
nitrogen gas with small amounts a second gas. [11C]Carbon
dioxide (11CO2) and [
11C]methane (11CH4), are formed,
when either small amounts oxygen or hydrogen are present
in the cyclotron target. Sometimes, these simple primary
precursors are used directly as labeling agents (e.g. 11CO2),
but more often they are converted via on-line synthetic
pathways into more reactive species before being used in
11C-labeling reactions. However, several reactive 11C-la-
beled precursors have been developed over the years [8],
but the 11C-precursors that will be discussed in this review
are displayed and highlighted in Fig. 1.
11C-methylation reaction
By far, the most common method in modern carbon-11
chemistry is heteroatom methylation using the methylating
agents [11C]methyl iodide (11CH3I) [9, 10] or [
11C]methyl
triflate (11CH3OTf) [11, 12]. This reaction can either be
performed using a traditional vial-based approach or
alternatively using solid support (‘‘on-cartridge’’ [13] or
‘‘in-loop’’ [14] methods), which is very convenient from an
automation prospective. A majority of the 11C-labeled
radiopharmaceuticals that are used on a regular basis, with
a few exceptions, are thus produced by these two methy-
lating agents. However, these methylating agents are
sluggishly reactive towards arylamines. Especially difficult
are substrates where the aryl group in a primary arylamine
electron density has been further reduced by an electron-
withdrawing group. In such situations, the more reactive
methylating agent, 11CH3OTf, may even fail to react.
However, Pike and co-workers presented a method that
utilized inorganic bases (e.g. Li2O) paired with DMF to
permit methylation of a wide range of arylamines using
11CH3I at room temperature [15]. Moreover, in a recent
study, the research group of Billard described the appli-
cation of 11CO2 as a C1 building block for the catalytic
methylation of amines [16]. Importantly, this one-pot
approach eliminates the time-consuming preparation of the
active methylating agent. The proposed mechanism is
outlined in Table 1. In brief, an appropriate amine pre-
cursor, initially traps 11CO2 to form complex 1, which is
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reduced in two-steps with ZnCl2/iPr and PhSiH3, to furnish
the expected methylamine. It was realized that the 11CO2
trapping was dependent on the basicity of the amine in use,
varying between 65 and 80%. A large number of sub-
strates, including the well-established radioligand,
[11C]PIB [17], was obtained in acceptable yields (Table 1).
In recent years, the application of 11CH3I in transition-
metal-mediated reactions has become more widespread for
11C-labeling of radiopharmaceuticals [18, 19]. Figure 2
shows a brief overview of compounds labeled via Pd-me-
diated 11C-methylation. Two radioligands for the serotonin
transporter, [p-methyl-11C]MADAM [20] and [11C]5-
methyl-5-nitroquipazine [21], as well as a novel radioli-
gand for the nicotinic acetylcholine receptor [22]
(nAChRs) was methylated using the transition-metal-me-
diated reaction. [11C]A-85,380 displayed favorable in vivo
properties for quantification of the nAChRs in living brain
[23]. The nAChRs represents major neurotransmitter
receptor responsible for various brain functions, and
changes in the density of nAChRs have been reported in
various neurodegenerative diseases, including Alzheimer’s
disease and Parkinson’s disease [24]. Another example is
the radiosynthesis of the 15R-[11C]TIC methyl ester, a
prostacyclin receptor radioligand, which was the first
radioligand approved for investigation in humans [25, 26].
The same radioligand was later used to image variations in
organic anion-transporting polypeptide function in the
human hepatobiliary transport system [27].
Two of the most applied cross-coupling reactions in
radiochemical synthesis today are the Stille and Suzuki
reactions, where organotin and organoborane compounds
function as starting materials, respectively, and 11CH3I as a
coupling partner. A wide variety of functional groups such
as amino, hydroxyl, or carboxylate are tolerated in these
reactions and protective groups are usually not required.
One unfortunate drawback with Stille coupling is, however,
the inherent toxicity of the organotin reagent. Because of
the regulatory aspects associated with radiopharmaceuti-
cals that are to be used in human subjects, the less toxic
organoborate substrates are usually preferred. As an alter-
native route to 11C-methylated arenes, Kealey and co-
workers describe a convenient two-step Pd-mediated cross-
coupling of 11CH3I with organozinc reagents (Scheme 1)
[28]. The Nagishi-type reaction was used to synthesize a
series of simple arenes in excellent yields. The same pro-
tocol was finally applied in the radiosynthesis of an
mGluR5 radioligand, [11C]MPEP [29]. Even though
organozinc reagents are known to be moisture sensitive, it
is much likely, that in the near future, Nagishi cross-cou-
pling reaction will be considered a good alternative to the
established protocols.
Enolates are a class of carbon centered nucleophiles that
shortly may have a major importance in the radiopharma-
ceutical community. To generate an active enolate, a strong
base, such as alkyl lithium or lithium diisopropylamide is
typically needed. Using lithium bases to remove a a-proton
is not always adequate because of their moisture sensitiv-
ity. However, in 2010, two methods for the synthesis of
11C-labeled arylpropionic acid derivatives have been pre-
sented [30, 31]. The rapid sp3–sp3 11C-methylation reaction
relied on the formation of benzylic enolates, using either
sodium hydride or tetrabutylammonium fluoride as base
Fig. 1 Some transformations in
carbon-11 radiochemistry.
Those discussed in this review
are highlighted in ovals
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(Scheme 2). The reaction proceeds smoothly under mild
conditions. However, until recently, the 11C-methylated
product formed under these conditions was obtained in low
enantiomeric purity. The use of chiral phase-transfer cat-
alyst has enabled enantioselective synthesis of the amino
acid, [11C]L-alanine, in high enantioselective purity
[enantiomeric excess (ee) of 90%] [32].
Moreover, this year, our group presented a novel (car-
bonyl)cobalt-mediated, and microwave-assisted, car-
bonylative protocol for the direct preparation of 11C-
labeled aryl methyl ketones using 11CH3I as the labeling
agent [33]. The method uses CO2(CO)8 as a combined aryl
halide activator and carbon monoxide source for the
carbonylation reaction. The method was used to label a set
of functionalized (hetero)arenes with yields ranging from
22 to 63% (Scheme 3).
11CO2-fixation reaction
[11C]Carbon dioxide is in itself a highly attractive starting
material for radiolabeling, since it is produced directly in
the cyclotron. However, due to low chemical reactivity, the
direct incorporation of CO2 into organic molecules poses a
significant challenge. High pressures, high temperatures or
catalysts are commonly required to activate the molecule.
Table 1 Direct 11C-methylation of amines using 11CO2
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The traditional method for 11CO2 ‘‘fixation’’ is the Grig-
nard reaction, which involves the conversion of alkyl or
aryl magnesium halides to [11C]carboxylic acids. However,
Grignard reagents require great care and the rigorous
exclusion of atmospheric moisture and CO2 during storage
and manipulation. To overcome these limitations, two
Fig. 2 Radiopharmaceuticals
labeled via metal-mediated 11C-
methylation
Scheme 1 Pd-mediated cross-
coupling of 11CH3I with
organozinc reagent
Scheme 2 Synthesis of 11C-labeled 2-arylpropionic acids and their methyl esters
Scheme 3 The formation of aryl methyl ketones via direct 11C-acetylation with 11CH3I
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independent research groups presented what arguably can
be viewed as the most ground-breaking advance in the field
of carbon-11 chemistry since 11CH3I was introduced in the
early 1970s. The innovative method, that was inspired by
the recent advances in ‘‘green chemistry’’ and reported in
2009, uses sub-milligram amounts of precursor compound,
reacts at low temperature (typically room temperature), for
1–3 min reaction time and does not require advanced
technical equipment [34, 35]. To overcome the low reac-
tivity of CO2, organic amines such as DBU or BEMP act as
organomediators by activating CO2 prior to the covalent
bond formation [36, 37]. The first report on 11CO2 fixation
was on the synthesis of 11C-labeled carbamates. However,
the scope of the method was later broadened to include
[11C]ureas and [11C]oxazolidinones (Scheme 4) [38], via
the formation of an 11C-labeled isocyanate or carbamoyl
anhydride intermediate. A number of drug-like molecules
have been prepared using this methodology in recent years
(2009–2016, see Fig. 3). These includes, the carbonyl
analogue radioligand of [11C-methyl]AR-A014418, a
compound developed for imaging of synthase kinase 3b
(GSK-3b) [39]. However, unfortunately, the in vivo eval-
uations of AR-A014418 revealed an undesirably low brain
uptake [40]. Moreover, two potent and irreversible fatty
acid amide hydrolase (FAAH) inhibitors, [11C]PF-
04457845 [41] and [11C]CURB [42], have also been pre-
pared. The latter, [11C]CURB, have recently been trans-
lated to a clinical setting for reginal quantification of
FAAH activity in human brain [43]. Furthermore, the
reversible monoamine oxidase B (MAO-B) radioligand,
[11C]SL25.1188, previously prepared using the technical
demanding [11C]phosgene approach, was radiolabeled in
high yield via 11CO2-fixation [44, 45]. This radioligand
was recently translated for human PET imaging [46].
Later, on a related subject, Dheere and co-workers
presented a further refinement to the methodology to
obtain [11C]ureas from less reactive amines, such as
anilines [47, 48]. Once again, DBU was used to trap
11CO2 in solution, but in this case, it was shown that
treatment of the carbamate anion intermediate (5) with
Mitsunobu reagents, DBAD and PBu3, provided the
corresponding asymmetric ureas in high radiochemical
conversion (Scheme 5).
In the interest of expanding the scope of 11CO2 as a
feedstock in radiochemical synthesis, copper-mediated
approaches to carboxylic acids and their derivatives have
been described [49, 50]. In the most recent example, the
combination of Cu(I) with boronic esters enabled CO2
activation in the presence of a soluble fluoride additive and
an organic base. In this reaction, the use of TMEDA was
found to be crucial for obtaining high radiochemical yields,
an observation likely explained by its dual action as both a
trapping agent for 11CO2 and a ligand for the copper cat-
alyst. A variety of functional groups were tolerated under
optimized conditions, and the generated 11C-carboxylic
acids could be further converted into either amines or
esters, as exemplified in the one-pot two-step preparation
of a candidate radioligand for the oxytocin receptor.
Scheme 4 Proposed pathways of 11C-labeled urea and carbamates via 11CO2-fixation chemistry [37]
Clin Transl Imaging
123
Carbonylation reactions using 11CO
[11C]Carbonmonoxide (11CO) hasmany attractive features as
a synthon for PET radiochemistry, including its facile pro-
duction [51, 52] and high versatility in transition-metal-me-
diatedcarbonylation reactions [53–56].Thewidespreaduse of
11CO in radiosynthetic chemistrywas until recently hampered
by its poor reactivity. Several solutions have been introduced
to overcome the above shortcomings, both from a technical
and chemical point of view [57–60]. A breakthrough was
reported in 1999,whereKihlberg and co-workers introduced a
method wherein 11CO was allowed to react in a small auto-
clave under high solvent pressure ([350 Bar) [61]. The high-
pressure reactor methodology exhibited nearly quantitative
11CO trapping efficiency and high radiochemical yield. Even
though thismethodhas exemplified the importance of 11COas
a labeling precursor it has not gained broad adoption in the
PET radiochemistry community. This can partly be attributed
to the overall complexity of the autoclave system and the
relatively high level of service needed to maintain the system
operational. Moreover, the repeated use of an integrated
stainless steel reactor may infer issues related to transition
metal build up over time, which is problematic in reaction
development and system validation.
In recent years, the development of low-pressure tech-
niques has been in focus. In 2012, an efficient protocol was
Fig. 3 Radiopharmaceuticals labeled via 11CO2-fixation chemistry
Scheme 5 Proposed pathway for 11C-labeled urea formation using Mitsunobu reagents
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reported by Eriksson and co-workers, in which 11C-car-
bonylation reactions were achieved without the need for
high-pressure equipment [62]. The high solubility of xenon
gas in organic solvents was exploited as an effective way of
transferring 11CO into a sealed standard disposable reaction
vial (1 ml) without significant pressure increase. The utility
of the method was exemplified by 11C-labeling of amides,
ureas, and esters. The use of disposable glass reaction
vessels eliminates carry over issues associated with the
high-pressure autoclave system, thus simplifying the tran-
sition to clinical applications. Recently, three reports were
published using the same 11CO transfer protocol (Fig. 4).
Windhorst et al. produced three 11C-labeled acryl amide
radioligands for in vivo PET imaging of the tissue trans-
glutaminase (TG2) enzyme [63]. Moreover, with the
‘‘xenon-method’’ as the synthesis platform, the Uppsala-
group presented two novel approaches to 11C-carbonyl
labeled compounds. Firstly, a new multicomponent reac-
tion for 11C-labeling of sulfonyl carbamates was described
[64]. The method was further applied as a synthetic tool for
the in vivo evaluation of an angiotensin II receptor subtype
2 (AT2R) agonist. Secondly, a method to access
11C-la-
beled alkyl amides via a thermally-initiated radical reduc-
tive dehalogenative approach [65]. One of the restrictions
of transition-metal-mediated reactions is the competing b-
hydride elimination of the resulting metal-substrate inter-
mediate, which precludes the use of alkyl electrophiles
containing b-hydrogen. This unfortunate competing reac-
tion is non-excitant for radical pathways. A series of un-
activated alkyl iodides was successfully converted into the
corresponding alkyl amide in good RCY, including the
radiosynthesis of an 11b-HSD1 inhibitor.
Specific Pd-complexes have also been shown to trap
11CO at ambient pressure and without the need for any
high-pressure equipment [66, 67]. XantPhos, a hindered
bidentate phosphine ligand, in combination with palladium
(l-cinnamyl) chloride dimer were found to be excellent for
promoting 11C-carbonylation reactions. Notably, in this
study it was discovered that, depending on the palladium-
ligand complex in use, different 11CO trapping efficiency
Fig. 4 Radiopharmaceuticals




was observed (Table 2). The reaction proceeds smoothly at
close to atmospheric pressure with aryl halides or triflates
as substrates using simple disposable glass vials. This
method was recently also applied in the preparation of
well-known D2 radioligand, [
11C]raclopride, but with the
carbon-11 labeled in the more metabolically stable car-
bonyl group (Fig. 4) [68]. Interestingly, in a direct com-
parison between ([11C]methyl)raclopride (produced using
the standard 11C-methylation approach) and
([11C]carbonyl)raclopride, both radioligands showed simi-
lar in vivo properties with regards to quantitative outcome
measurements, radiometabolite formation and protein
binding.
The protocol was further improved by Andersen and co-
workers, where pre-generated (Aryl)Pd(I)Ln oxidative
addition complexes were utilized as precursors for the
following 11C-carbonylation reaction [69]. This is exem-
plified in the preparation of [11C- carbonyl]raclopride in
Table 2 Ligand effect in 11C-aminocarbonylation reaction at ambient pressure






1 dppe 78 31 21 
2 (S)-BINAP 92 18 3 
3 dppp 95 63 31 
4 dppb 99 40 10 
5 dppf 106 85 30 
6 DPEphos 108 55 19 
7 XantPhos 110 >99 54 
8 dcpp - 11 0 
9 PPh3 - 21 7 
10 SPhos - 9 4 
11 tBu-XantPhos 140 12 2 
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Scheme 6. The isolated complexes, (Aryl)Pd(I)Ln, have
already undergone the potentially challenging oxidative
addition step before their employment in carbonylative
11C-labeling. In this case, Pd-XantPhos complexes
appeared to be among the most reactive precursors,
although, electron-deficient aryl precursors demanded Pd-
P(t-Bu)3 to prevent aryl scrambling with phosphine ligand.
The simplicity of these low-pressure techniques, and
especially the ‘‘xenon-method’’ delivery protocol, may
offer a potential for being widely adopted in radiophar-
maceutical research and development.
As mentioned previously, one restriction with transition-
metal-mediated reactions is the competing b-hydride
elimination. However, in contrast to Pd or Rh catalyst,
nickel has been known to suppress the b-hydride elimina-
tion reaction. In the light of this, Rahman and co-workers
recently reported the first successful use of nickel-mediated
carbonylative cross-coupling of non-activated alkyl iodides
using 11CO at ambient pressure [70]. The best conditions
identified in this study made use of a nickel(0) precatalyst,
Ni(COD)2, in the presence of bathophenantroline as ligand
(Table 3). Six model compounds were successfully radio-
labeled in acceptable to good yields. However, more data is
required to establish if the method is suitable of preparing
more complex molecules.
Other recent advances in carbon-11 chemistry
Hydrogen cyanide is well established as a versatile pre-
cursor in PET radiopharmaceutical chemistry [71–73], and
its involvement in metal-mediated cyanation of aryl
Scheme 6 Labeling based on pre-isolated (Aryl)Pd(I)Ln complexes with
11CO
Table 3 Nickel-mediated 11C-aminocarbonylation of iodoalkyl compounds
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(pseudo)halides is well documented [74, 75]. A limitation
of such reactions is that they require rather harsh condi-
tions, such as high temperature, long reaction times, and
inorganic bases (e.g. KOH), which reduces the substrate
scope. Recently, a novel method was reported describing
near instantaneous, room temperature Pd-mediated cou-
pling of [11C]HCN to aryl halides or triflates [76]. The
method is based on sterically hindered biaryl phosphine
ligands (Table 4) that facilitate rapid transmetalation with
[11C]HCN and reductive elimination of aryl nitriles at
ambient temperature. A wide variety of (hetero)arenes and
drug-like molecules were radiolabeled in high yields,
including the j-opioid receptor radioligand
[11C]LY2795050 (Fig. 5). Moreover, two known antide-
pressants were also 11C-labeled in this study. This further
illustrates the usefulness of the current method in the
preparation of radiopharmaceuticals.
Carbon disulfide, the sulfur analogue of carbon dioxide,
has recently been synthesized on-line from 11CH3I using
either P2S5 and elemental sulfur (S8) at elevated tempera-
tures in excellent yields [77, 78]. Due to the weaker C=S
bond CS2 is considered more reactive than CO2. Moreover,
CS2 reacts very rapidly with many primary amines at room
temperature to form the dithiocarbamate salts, which in
turn, upon treatment with a suitable alkylating reagent will
give the corresponding thiocarbamates. Heating, on the
other hand, induces rearrangement to form the symmetrical
thiourea (Scheme 7). Some model compounds were radi-
olabeled using this protocol in near quantitative yields.
Finally, a progesterone receptor agonist, Tanaproget, was
also produced in high RCY (Fig. 5).
Lastly, an improved, mild synthesis of [11C]formaldehyde
have opened up new to carbon-11 labeled radiopharma-
ceuticals [79]. The treatment of trimethylamine N-oxide
Table 4 Pd-mediated radiosynthesis of [11C]aryl nitriles
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with 11CH3I at room temperature gave
11CH2O in a one-pot
reaction. This novel preparation has been utilized by a
number of groups to generate new exciting compounds
(Fig. 5) [80, 81]. In addition, since [11C]formaldehyde was
reported already in 1972 [82], there are other molecules
previously reported in the literature that may now be syn-
thesized in a simplified fashion using this protocol.
Final remarks
The increasing importance of PET in drug development
and clinical research has motivated researchers to initiate
programs directly dedicated to development of new radi-
olabeling methods. This review summarizes some of the
most recent and promising strategies to obtain carbon-11
Fig. 5 Radiopharmaceuticals
labeled using either 11CN, 11CS2
and 11CH2O





labeled products. In the past two decades, and well before
this, efforts have brought to bear an impressive range of
methods for 11C-radiochemistry. However, there are still
issues to be addressed. Take for example, the heteroatom
11C-methylation reaction, which is now considered as an
established method by the broader radiochemical commu-
nity. Why is this? The main reason is the access to dedi-
cated commercially available radiochemical equipment for
this radiochemistry. Consequently, to streamline new
methodologies, and make them widely available, new
radiochemical equipment is needed. A possible approach to
attack the problem could be to develop radiosynthesis
equipment with a higher flexibility. A fundamental ques-
tion is if microscale technology (microfluidic or microre-
actor) can provide a breakthrough in radiochemistry? Its
compact design, flexible attributes, and its suitability for
automation make microscale technology an ideal platform
for performing the rapid radiolabeling reactions required
for PET. So far, efforts made to adapt microscale tech-
nology for PET radiolabeling purposes have focused on
proof-of-principle studies and to illustrate the advantages
associated with the technology and significant further
development is needed for the technology to reach its full
potential. Although the authors recognize the importance of
microreactor technologies, other technical approaches
towards the development of more flexible radiochemical
synthesis equipment are equally attractive at this point.
Regardless of which direction is taken in the future, we
firmly believe that a stronger collaboration between
radiochemists and technical engineers is vital for suc-
ceeding in the development of the next generation of PET
radiochemistry equipment.
Finally, radiochemistry is the foundation for PET
imaging. By broadening the spectrum of radiochemical
reactions within clinical PET radiochemistry, radio-
chemists will not only be able to increase the number of
compounds that can be labeled with carbon-11 but also
provide an increased opportunity to label a given com-
pound in different positions.
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